Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce episode artwork

EPISODE · Mar 18, 2026 · 9 MIN

Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda

NOW PLAYING

Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce

0:00 9:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 9 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on March 18, 2026.

What is this episode about?

FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!